PARIS, FRANCE: Sanofi announced today that it has entered into a definitive agreement to acquire ownership of Qunol, a U.S.-based, market-leading brand in health & wellness, focusing on the active ‘healthy aging’ segment.
Qunol offers CoQ10 and Turmeric products that support heart health and joint health, respectively. These products are backed by science literature and have strong brand equity and consumer loyalty. Qunol is a profitable double-digit growth brand in the Vitamin, Mineral and Supplements (VMS) category, one of the largest and fastest-growing consumer health categories in the U.S.
The acquisition of Qunol will strengthen Sanofi’s Consumer Healthcare’s (CHC) portfolio in the wellness category, filling one of its white spaces in the U.S. and unlocking an opportunity to accelerate its growth. The Qunol brand will benefit from Sanofi’s CHC resources to expand into other chronic conditions and develop its footprint outside the U.S.
Julie Van Ongevalle, Executive Vice President, Consumer Healthcare, Sanofi, said: “The acquisition of Qunol further strengthens our portfolio in the wellness category. It taps into the growing ‘healthy aging’ segment and fills one of our white spaces in the U.S., unlocking an opportunity for us to build on our U.S. presence and accelerate our growth. VMS now functions as long-term support for overall health and wellness where proactive preventive health has become the new norm post-pandemic. We are excited to welcome Qunol and, with this addition to our consumer healthcare portfolio, reinforce our commitment to bring more health into the hands of people.”
Peter Boutros, CEO, Quten Research Institute, LLC, said: “Qunol is looking forward to joining Sanofi’s consumer healthcare team and developing synergies that will further drive brand awareness for our products with our consumers and customers. With Sanofi, we have the opportunity to further grow in the U.S. and beyond, tapping into Sanofi Consumer Healthcare’s commercial breadth and strength.”
The transaction is subject to customary closing conditions, including applicable regulatory approvals. The acquisition is expected to close Q3 2023.
Allfunds to acquire local paying agent business of Iccrea Banca in Italy